Acatinib 100 mg Tablet
Brand Name: Acatinib
Molecule: Acalabrutinib
Strength: 100 mg
Quantity: 60 Capsules
Form: Capsule
Packaging Type: Bottle
Manufacturer/Marketed By: Ziska Pharmaceuticals Ltd
Country of Origin: Bangladesh
Please fill in the details below, and we’ll get back to you as soon as possible
Similar Products:
Description
Acatinib 100 mg Tablet is a targeted anticancer agent used for specific types of cancer. It helps slow tumor growth by blocking key cellular pathways. Use only under specialist supervision.
Benefits
-
Targets the specific molecular driver of cancer, enabling more focused therapy.
-
Can slow or halt tumor growth and spread in eligible patients.
-
Potential to improve progression-free survival when used appropriately.
-
Oral tablet formulation offers convenience relative to some injectable therapies.
Indications and Usage
-
Used for the treatment of [specific cancer type as per prescribing information; e.g., non-small cell lung cancer (NSCLC) with certain biomarkers].
-
May be used when tumors exhibit particular molecular targets or mutations, as determined by diagnostic testing.
-
Should be used in combination with other therapies as specified by the oncologist.
-
Strictly for use under specialist cancer-treatment supervision.
How it Works
Acatinib targets and inhibits key signaling proteins that cancer cells rely on to grow and divide (for example, certain tyrosine kinases). By blocking these pathways, the drug disrupts the cancer’s growth mechanisms, leading to slowed tumor progression or cell death in susceptible tumors.
Dosage & Administration
-
The typical dose is 100 mg tablet, taken as directed by the oncologist (e.g., once or twice daily depending on regimen).
-
Take at the same time each day.
-
Swallow whole with a full glass of water; may be taken with or without food unless advised otherwise.
-
Do not modify or skip doses without consulting the specialist.
-
Regular monitoring (blood tests, liver function, imaging studies) is required to evaluate response and manage toxicity.
Side Effects
Common side effects may include:
-
Fatigue or weakness
-
Nausea and/or vomiting
-
Loss of appetite
-
Diarrhea
-
Skin rash or changes
Serious side effects (seek medical attention immediately):
-
Severe liver enzyme elevation or liver injury
-
Pulmonary problems (e.g., interstitial lung disease)
-
Significant blood count abnormalities (e.g., neutropenia, thrombocytopenia)
-
Severe allergic reactions
-
Unexpected bleeding or clotting events
Warning and Precaution
-
Use only if indicated by the specialist and if appropriate biomarker/mutation status is confirmed.
-
Avoid in patients with known severe liver or kidney impairment unless specialist advises otherwise.
-
Monitor for lung or respiratory symptoms; discontinue and investigate if interstitial lung disease suspected.
-
Caution if history of bleeding, clotting or cardiovascular disease.
-
Pregnancy & breastfeeding: not recommended unless clearly needed and supervised by oncology specialist.
-
This medicine does not cure cancer; it is part of a broader treatment plan. Patients must discuss all risks, benefits and alternatives with their oncologist.
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »April 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.